Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...4849505152535455565758...208209»
  • ||||||||||  SHR-A2102 / Jiangsu Hengrui Pharma
    Enrollment open:  SHR-A2102-201: A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors (clinicaltrials.gov) -  Jan 4, 2025   
    P1/2,  N=80, Recruiting, 
    Daily administration of noiiglutide using a titration method was well tolerated by Chinese obese participants without DM and showed potential therapeutic effect for weight loss. Not yet recruiting --> Recruiting
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
    Enrollment closed, Trial completion date, Trial primary completion date:  Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer (clinicaltrials.gov) -  Jan 4, 2025   
    P3,  N=443, Active, not recruiting, 
    Not yet recruiting --> Recruiting Enrolling by invitation --> Active, not recruiting | Trial completion date: May 2023 --> Apr 2025 | Trial primary completion date: Dec 2022 --> Apr 2025
  • ||||||||||  AiRuiKa (camrelizumab) / Elevar Therapeutics
    Enrollment change, Trial termination:  A SHR-1210 BE Study on Healthy Subjects (clinicaltrials.gov) -  Jan 4, 2025   
    P1,  N=12, Terminated, 
    Enrolling by invitation --> Active, not recruiting | Trial completion date: May 2023 --> Apr 2025 | Trial primary completion date: Dec 2022 --> Apr 2025 N=118 --> 12 | Recruiting --> Terminated; Sponsor's R&D Strategy adjusted
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment closed, Trial completion date, Trial primary completion date:  PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery (clinicaltrials.gov) -  Jan 3, 2025   
    P2,  N=65, Active, not recruiting, 
    Trial primary completion date: Dec 2024 --> Jan 2026 Recruiting --> Active, not recruiting | Trial completion date: Feb 2024 --> Jun 2025 | Trial primary completion date: Aug 2022 --> Jun 2025
  • ||||||||||  Sulanda (surufatinib) / Hutchmed, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
    Trial completion date, Trial primary completion date:  Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer (clinicaltrials.gov) -  Jan 3, 2025   
    P1/2,  N=90, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Feb 2025 --> Jun 2025 | Trial primary completion date: Jul 2024 --> Dec 2024
  • ||||||||||  AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
    Enrollment open:  MA-NPC-II-004: Adebrelimab and Chemoradiotherapy in High-risk LANPC (clinicaltrials.gov) -  Jan 3, 2025   
    P2,  N=50, Recruiting, 
    Trial completion date: Feb 2025 --> Jun 2025 | Trial primary completion date: Jul 2024 --> Dec 2024 Not yet recruiting --> Recruiting
  • ||||||||||  Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
    Journal:  Chronic myelogenous leukemia coexpressing V-e16a2, V-e13a2, e13a2, and e14a2 BCR::ABL1 fusion transcripts: a case report and review of the literature. (Pubmed Central) -  Dec 30, 2024   
    A 66-year-old Chinese female patient was diagnosed with chronic myeloid leukemia-chronic phase (CML-CP) expressing four BCR::ABL1 transcripts, including variant e16a2(V-e16a2), variant e13a2(V-e13a2), classical e13a2, and e14a2 transcripts. The patient was treated with flumatinib, a tyrosine kinase inhibitor (TKI).The variant transcripts reported exhibited a favorable response to TKI, and attention should be directed toward monitoring variant transcripts.
  • ||||||||||  otesaconazole (VT-1161) / Mycovia Pharma, Noxafil (posaconazole) / Merck (MSD), Cresemba (isavuconazonium sulfate) / Astellas, Basilea
    Preclinical, Journal:  The Molecular Basis of the Intrinsic and Acquired Resistance to Azole Antifungals in Aspergillus fumigatus. (Pubmed Central) -  Dec 27, 2024   
    A crowded conformationally sensitive region involving the BC-loop, helix I, and the heme makes AfCYP51A T289 primarily responsible for resistance to fluconazole, VT-1161, and the agrochemical difenoconazole. The Y121F T289A combination was required for higher level acquired resistance to fluconazole, VT-1161, difenoconazole, and voriconazole, and confirms posaconazole, isavuconazole and possibly ravuconazole as preferred treatments for target-based azole-resistant aspergillosis due to such a combination of mutations.
  • ||||||||||  SHR-1222 / Jiangsu Hengrui Pharma
    Review, Journal:  Biochemical Mechanisms and Rehabilitation Strategies in Osteoporosis-Related Pain: A Systematic Review. (Pubmed Central) -  Dec 27, 2024   
    Pharmacological options such as NSAIDs, opioids, and new agents like SHR-1222, along with surgical interventions like percutaneous vertebroplasty, offer additional pain reduction, especially when included in individualized rehabilitation projects; This review highlights advancements in understanding osteoporotic pain mechanisms and identifies promising treatments. Integrating targeted therapies and rehabilitation strategies can enhance patients' pain relief.
  • ||||||||||  ruzaltatug rezetecan (SHR-A2009) / Jiangsu Hengrui Pharma
    Trial completion, Trial completion date, Trial primary completion date:  SHR-A2009-I-102: The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Dec 27, 2024   
    P1,  N=19, Completed, 
    Integrating targeted therapies and rehabilitation strategies can enhance patients' pain relief. Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Apr 2024 | Trial primary completion date: Jun 2025 --> Apr 2024
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    New P2 trial:  LIAES: Liposomal Irinotecan and Apatinib in ES-SCLC (clinicaltrials.gov) -  Dec 26, 2024   
    P2,  N=30, Recruiting,